Tags

Type your tag names separated by a space and hit enter

Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids.
Fertil Steril. 2003 Dec; 80(6):1495-501.FS

Abstract

OBJECTIVE

To evaluate the effects of a low-dose DHEA supplementation on hormonal parameters in early and late postmenopausal women.

DESIGN

Prospective case study.

SETTING

Postmenopausal women in a clinical research environment.

PATIENT(S)

Twenty postmenopausal women were divided in two groups according to age (50-55 and 60-65 years).

INTERVENTION(S)

All patients underwent hormonal evaluation before and at 3, 6, 9, and 12 months of therapy (25 mg/d of DHEA orally). Pelvic ultrasound examination and Kupperman score were performed before and after 3, 6, and 12 months of therapy.

MAIN OUTCOME MEASURE(S)

Plasma DHEA, DHEAS, estrone (E1), E2, P, androstenedione (A), T, dihydrotestosterone, 17alpha-hydroxyprogesterone (17-OHP), cortisol (F), allopregnanolone, beta-endorphin, sexual hormone-binding globulin (SHBG), LH, FSH, growth hormone (GH), and insulin-like growth factor-1 (IGF-1) concentrations.

RESULT(S)

The levels of all the steroids that derive from DHEA metabolism increased in plasma with DHEA administration. Also neurosteroids (namely allopregnanolone) and endorphin showed increased plasma levels, whereas both gonadotropins were significantly reduced. Endometrial thickness did not change throughout the study period.

CONCLUSION(S)

Administration of low doses (25 mg) of DHEA positively modulates several endocrine parameters in early and late postmenopausal women, inducing the increase of the androgenic, estrogenic, and progestogenic milieu and reducing the climateric symptoms, similarly to estroprogestin replacement therapy. These data suggest that DHEA supplementation is a more effective replacement therapy than a simple "dietary supplement."

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Modena, Modena, Italy. algen@unimore.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

14667889

Citation

Genazzani, Alessandro D., et al. "Long-term Low-dose Dehydroepiandrosterone Oral Supplementation in Early and Late Postmenopausal Women Modulates Endocrine Parameters and Synthesis of Neuroactive Steroids." Fertility and Sterility, vol. 80, no. 6, 2003, pp. 1495-501.
Genazzani AD, Stomati M, Bernardi F, et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril. 2003;80(6):1495-501.
Genazzani, A. D., Stomati, M., Bernardi, F., Pieri, M., Rovati, L., & Genazzani, A. R. (2003). Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertility and Sterility, 80(6), 1495-501.
Genazzani AD, et al. Long-term Low-dose Dehydroepiandrosterone Oral Supplementation in Early and Late Postmenopausal Women Modulates Endocrine Parameters and Synthesis of Neuroactive Steroids. Fertil Steril. 2003;80(6):1495-501. PubMed PMID: 14667889.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. AU - Genazzani,Alessandro D, AU - Stomati,Massimo, AU - Bernardi,Francesca, AU - Pieri,Matteo, AU - Rovati,Lucio, AU - Genazzani,Andrea R, PY - 2003/12/12/pubmed PY - 2004/1/22/medline PY - 2003/12/12/entrez SP - 1495 EP - 501 JF - Fertility and sterility JO - Fertil Steril VL - 80 IS - 6 N2 - OBJECTIVE: To evaluate the effects of a low-dose DHEA supplementation on hormonal parameters in early and late postmenopausal women. DESIGN: Prospective case study. SETTING: Postmenopausal women in a clinical research environment. PATIENT(S): Twenty postmenopausal women were divided in two groups according to age (50-55 and 60-65 years). INTERVENTION(S): All patients underwent hormonal evaluation before and at 3, 6, 9, and 12 months of therapy (25 mg/d of DHEA orally). Pelvic ultrasound examination and Kupperman score were performed before and after 3, 6, and 12 months of therapy. MAIN OUTCOME MEASURE(S): Plasma DHEA, DHEAS, estrone (E1), E2, P, androstenedione (A), T, dihydrotestosterone, 17alpha-hydroxyprogesterone (17-OHP), cortisol (F), allopregnanolone, beta-endorphin, sexual hormone-binding globulin (SHBG), LH, FSH, growth hormone (GH), and insulin-like growth factor-1 (IGF-1) concentrations. RESULT(S): The levels of all the steroids that derive from DHEA metabolism increased in plasma with DHEA administration. Also neurosteroids (namely allopregnanolone) and endorphin showed increased plasma levels, whereas both gonadotropins were significantly reduced. Endometrial thickness did not change throughout the study period. CONCLUSION(S): Administration of low doses (25 mg) of DHEA positively modulates several endocrine parameters in early and late postmenopausal women, inducing the increase of the androgenic, estrogenic, and progestogenic milieu and reducing the climateric symptoms, similarly to estroprogestin replacement therapy. These data suggest that DHEA supplementation is a more effective replacement therapy than a simple "dietary supplement." SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/14667889/Long_term_low_dose_dehydroepiandrosterone_oral_supplementation_in_early_and_late_postmenopausal_women_modulates_endocrine_parameters_and_synthesis_of_neuroactive_steroids_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015028203022532 DB - PRIME DP - Unbound Medicine ER -